Phase III
Beyond's analysis on Phase III
- — Apnimed prices upsized IPO to fund sleep‑disorder drug pipeline
- — Sanofi halts global development of its OX40‑ligand antibody amlitelimab for atopic dermatitis, removing a potential competitor to Dupixent and cutting related R&D spend
- — Ipsen’s Dysport achieves first positive Phase III results for both episodic and chronic migraine, opening a new migraine therapy avenue
Recent news mentioning Phase III
- — Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
- — Norroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC
- — Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III
- — Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- — U.S. Air Force Selects LGNDX for Phase III Deployment of Defense Acquisition Platform
- — GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth
- — Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
- — FirstService Residential Expands in Southern Delaware, Welcoming Sea Colony East Phase III Condominium to Its Premier Portfolio
- — Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
- — InnoCare's TYK2 Inhibitor Fadeucravacitinib (ICP-488) Meets Primary Endpoint in Phase III Psoriasis Study